You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 11, 2024

FUROSEMIDE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Furosemide patents expire, and what generic alternatives are available?

Furosemide is a drug marketed by Abraxis Pharm, Accord Hlthcare, Am Regent, Amneal Pharms Co, Areva Pharms, Astrazeneca, Avet Lifesciences, Baxter Hlthcare Corp, Eugia Pharma, Fresenius Kabi Usa, Gland Pharma Ltd, Hikma, Hospira, Igi Labs Inc, Intl Medication, Mankind Pharma, Marsam Pharms Llc, Meitheal, Saba Ilac Sanayive, Sagent, Smith And Nephew, Warner Chilcott, Watson Labs, Wockhardt, Wyeth Ayerst, Pharmobedient Cnsltg, Ani Pharms, Chartwell Rx, Epic Pharma Llc, Graviti Pharms, Ipca Labs Ltd, Kalapharm, Leading, Mylan, Prinston Inc, Strides Pharma, Sun Pharm Inds Inc, Sun Pharm Industries, Superpharm, and Watson Labs Teva. and is included in sixty-five NDAs.

The generic ingredient in FUROSEMIDE is furosemide. There are twenty-two drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the furosemide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Furosemide

A generic version of FUROSEMIDE was approved as furosemide by HIKMA on November 10th, 1983.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for FUROSEMIDE?
  • What are the global sales for FUROSEMIDE?
  • What is Average Wholesale Price for FUROSEMIDE?
Drug patent expirations by year for FUROSEMIDE
Drug Prices for FUROSEMIDE

See drug prices for FUROSEMIDE

Drug Sales Revenue Trends for FUROSEMIDE

See drug sales revenues for FUROSEMIDE

Recent Clinical Trials for FUROSEMIDE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of DelawareN/A
National Heart, Lung, and Blood Institute (NHLBI)N/A
University Hospital, ToursPhase 3

See all FUROSEMIDE clinical trials

Pharmacology for FUROSEMIDE
Drug ClassLoop Diuretic
Physiological EffectIncreased Diuresis at Loop of Henle
Medical Subject Heading (MeSH) Categories for FUROSEMIDE
Anatomical Therapeutic Chemical (ATC) Classes for FUROSEMIDE

US Patents and Regulatory Information for FUROSEMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc FUROSEMIDE furosemide TABLET;ORAL 091258-001 Apr 1, 2014 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Chartwell Rx FUROSEMIDE furosemide TABLET;ORAL 018413-001 Nov 30, 1983 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs FUROSEMIDE furosemide INJECTABLE;INJECTION 070604-001 Jan 2, 1987 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Watson Labs FUROSEMIDE furosemide TABLET;ORAL 018369-002 May 14, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.